Understanding the Challenge
Heart disease remains the top cause of death in the U.S., with many individuals unaware they have the condition until it’s too late. Cleerly, a startup focused on cardiovascular imaging, is working to change this reality. By utilizing advanced AI technology to analyze CT scans, Cleerly aims to detect early-stage coronary artery disease. This proactive screening approach is similar to established cancer detection methods like mammograms and colonoscopies.
Key Developments
- Cleerly is conducting a large clinical trial to demonstrate that its screening method can identify heart issues in asymptomatic individuals more effectively than traditional tests.
- The company recently raised $106 million in a Series C extension round, led by Insight Partners and supported by Battery Ventures.
- Cleerly’s algorithms have already received FDA clearance for diagnosing symptomatic patients, and Medicare has approved coverage for its plaque analysis test.
- The AI-driven method is less invasive than traditional tests, making it a more appealing option for patients and insurers alike.
The Bigger Picture
The work Cleerly is doing is crucial, as early detection of heart disease can save lives and reduce healthcare costs. With growing investor interest and a clear pathway to regulatory approval, Cleerly is positioned to make a significant impact in the healthcare industry. As the company continues to expand its reach, it may help millions of individuals receive the timely care they need, ultimately reducing the burden of heart disease in society.
